PortfoliosLab logo

Halozyme Therapeutics, Inc. (HALO)

Equity · Currency in USD
Sector
Healthcare
Industry
Biotechnology
ISIN
US40637H1095
CUSIP
40637H109

HALOPrice Chart


Chart placeholderClick Calculate to get results

HALOPerformance

The chart shows the growth of $10,000 invested in Halozyme Therapeutics, Inc. on Jan 5, 2010 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $58,200 for a total return of roughly 482.00%. All prices are adjusted for splits and dividends.


HALO (Halozyme Therapeutics, Inc.)
Benchmark (S&P 500)

HALOReturns in periods

Returns over 1 year are annualized

PeriodReturnBenchmark
YTD-11.56%-2.17%
1M2.66%0.62%
6M-17.11%6.95%
1Y-21.21%22.39%
5Y25.57%15.44%
10Y13.77%13.73%

HALOMonthly Returns Heatmap


Chart placeholderClick Calculate to get results

HALOSharpe Ratio Chart

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Halozyme Therapeutics, Inc. Sharpe ratio is -0.37. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.

The chart below displays rolling 12-month Sharpe Ratio.


HALO (Halozyme Therapeutics, Inc.)
Benchmark (S&P 500)

HALODividends


Halozyme Therapeutics, Inc. doesn't pay dividends

HALODrawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


HALO (Halozyme Therapeutics, Inc.)
Benchmark (S&P 500)

HALOWorst Drawdowns

The table below shows the maximum drawdowns of the Halozyme Therapeutics, Inc.. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Halozyme Therapeutics, Inc. is 71.03%, recorded on Feb 10, 2016. It took 1069 trading sessions for the portfolio to recover.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-71.03%Jul 23, 2015140Feb 10, 20161069May 11, 20201209
-67.79%Mar 28, 201289Aug 2, 2012322Nov 13, 2013411
-59.65%Jan 24, 201473May 8, 2014263May 26, 2015336
-38.15%Feb 25, 2021201Dec 9, 2021
-37.69%May 4, 2010320Aug 8, 201179Nov 29, 2011399
-16.28%Dec 3, 201311Dec 17, 20134Dec 23, 201315
-14.96%Jan 8, 201021Feb 8, 201014Mar 1, 201035
-13.13%Aug 14, 202029Sep 24, 202018Oct 20, 202047
-9.97%Oct 26, 20205Oct 30, 20202Nov 3, 20207
-8.18%Jul 16, 202010Jul 29, 20206Aug 6, 202016

HALOVolatility Chart

Current Halozyme Therapeutics, Inc. volatility is 36.26%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.


HALO (Halozyme Therapeutics, Inc.)
Benchmark (S&P 500)

Portfolios with Halozyme Therapeutics, Inc.


Loading data...

More Tools for Halozyme Therapeutics, Inc.